Clinical Trial Update: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study of galcanezumab in youths aged 12 to 17 with chronic migraine, currently listed as active but not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Galcanezumab (galcanezumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Chronic Migraine | Phase 3 | Status: ACTIVE_NOT_RECRUITING